Avalo Therapeutics, Inc. AVTX R3KPHARMA

Q: What is the current share price of Avalo Therapeutics, Inc. (AVTX)?

As of 2026-09-19 21:16 PDT, Avalo Therapeutics, Inc. (AVTX) trades at $19.71 on NasdaqCM. Its 52-week range is $8.90 to $22.87.

Q: What is the market capitalisation of AVTX?

Avalo Therapeutics, Inc. (AVTX) has a market capitalisation of $1.06B on NasdaqCM.

Q: What is the P/E ratio of AVTX?

AVTX trades at a trailing price-to-earnings (P/E) ratio of -4.47. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.15.

Q: What is the return on equity (ROE) of AVTX?

AVTX has a return on equity (ROE) of -36.27%. Its return on capital employed (ROCE) is -70.45%.

Q: Is AVTX a good stock to buy?

This page provides a data-driven analysis of Avalo Therapeutics, Inc. (AVTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.avalotx.com

Company Profile ↓

$19.71

+117.19% 1Y

Mkt Cap$1.06B

P/E-4.47

P/B2.15

52W High$22.87

52W Low$8.90

Book Value$8.48

EPS (TTM)$-4.41

Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.05.

Recent Developments

Dec 2025 Revenue of $59.00K (-86.6% YoY); net profit $-78.26M.
Trailing 12 Months Year-on-year growth — revenue -86.6%.
5-Year Trend Long-term compounding — revenue CAGR -61.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-61.19%
1 Year:	-86.62%

Stock Price Performance

1 Year:	+117.19%
6 Months:	+13.86%
3 Months:	+54.71%
1 Month:	+7.59%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 77% of range

$8.90 $22.87

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)53.20 · Neutral

Price Performance

1M+7.59%

3M+54.71%

6M+13.86%

1Y+117.19%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -61.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-4.47

Industry PE

24.83

Forward P/E

-7.19

PEG Ratio

Book Value

$8.48

Price to Book

2.15

P/S

16,552.58

EV/EBITDA

-7.20

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-61.19%

Profit 5Y

Revenue (YoY)

-86.62%

Earnings (YoY)

Profitability & Returns

ROCE

-70.45%

ROE

-36.27%

ROA

-18.50%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.83

EPS (TTM)

$-4.41

Balance Sheet & Liquidity

Debt/Equity

0.05

Quick Ratio

18.94

Current Ratio

19.31

Debt

$242.00K

Total Assets

$490.78M

Current Assets

$88.83M

Working Capital

$77.23M

Ownership

Promoter Holding

1.69%

Chg in Prom Hold

-0.00%

FII / Inst Holding

133.51%

Chg in FII Hold

0.14%

Financial Snapshot

Enterprise Value

$1.06B

Total Revenue (TTM)

$59.00K

EBITDA

$-91.25M

Free Cash Flow

$-23.27M

Operating Cash Flow

$-68.29M

Shares Outstanding

53.63M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AVTX Avalo Therapeutics, Inc. R3KPHARMA	19.71	-4.47	$1.06B	0.00%	-70.45%	-36.27%	-61.19%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	384	157.80K	25.04M	-	4.48M	4.79M	4.07M	2.58M	1.39M	2.20M	2.75M	1.34M	1.11M	473.00K	3.35M	1.35M	1.17M	1.03M	14.95M	475.00K	643.00K	236.00K	0	0	249.00K	-	0	0	0	59.00K	0	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.00K	0	0	0	0	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105.00K	0	0	0	59.00K	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.67M	19.32M	19.20M	19.80M	20.90M	-
Operating Income	-2.48M	-2.89M	-1.96M	-	-4.94M	-3.49M	-5.96M	-	-1.90M	-1.77M	21.92M	-	-3.75M	-5.75M	-24.31M	-5.00M	-2.55M	-2.86M	-31.41M	-11.81M	-13.28M	-30.58M	-17.13M	-16.46M	-20.85M	-11.83M	4.09M	-8.79M	-7.15M	-3.75M	-32.77M	-9.57M	-12.86M	-	-14.67M	-19.32M	-19.20M	-19.74M	-20.90M	-31.52M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14.53M	-19.18M	-19.14M	-19.73M	-20.88M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13.14M	-20.75M	-30.61M	-13.59M	-19.62M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.00K	16.00K	11.00K	130.00K	12.00K	-
Net Income	-3.24M	-2.91M	-692.00K	-3.65M	-5.14M	-3.52M	-6.17M	-1.64M	-1.96M	-1.80M	18.72M	-3.09M	-3.88M	-6.01M	-24.60M	-7.45M	-6.22M	-4.02M	-21.12M	-13.28M	-13.46M	-30.68M	-17.11M	-17.39M	-22.05M	-12.99M	3.19M	-9.96M	-8.19M	-5.23M	-121.29M	98.46M	23.04M	-	-13.15M	-20.77M	-30.62M	-13.72M	-19.63M	-36.36M
Diluted EPS	-	-	-	-	-	-	-0.70	-	-0.19	-0.14	0.52	-0.11	-	-	-0.71	-	-	-	-	-	-	-	-	-	-2.35	-1.38	0.34	-204.00	-140.73	-26.83	-141.14	-14.07	-2.83	-	-1.25	-1.92	-2.19	-	-0.98	-0.83
R&D Expense	1.72M	1.88M	1.24M	1.75M	2.29M	2.50M	4.58M	773.00K	953.07K	493.65K	965.00K	1.96M	1.65M	1.08M	-	3.40M	-	-	-	-	-	2.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	0	1.15M	27.81M	7.03M	6.75M	6.70M	5.40M	18.05M	1.92M	441.00K	59.00K
Operating Income	-12.93M	-17.12M	-11.01M	-16.08M	13.89M	-35.38M	-16.14M	-72.84M	-82.13M	-37.44M	-27.35M	-68.51M	-72.92M
Net Income	-13.05M	-16.06M	-10.49M	-16.47M	11.87M	-40.05M	-16.07M	-63.50M	-84.38M	-41.66M	-31.54M	-35.13M	-78.26M
Diluted EPS	-	-	-4.71	-1.87	0.42	-1.20	-	-	-	-1,063.00	-113.58	-20.91	-5.84
R&D Expense	8.91M	12.24M	6.59M	10.15M	4.37M	5.79M	-	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	12.32M	21.66M	5.77M	42.81M	70.25M	36.11M	43.76M	80.21M	33.37M	20.99M	150.73M	116.46M
Total Equity	-11.38M	-17.85M	-26.33M	13.08M	207.00K	27.86M	20.91M	21.00M	24.56M	23.08M	-10.91M	7.30M	133.03M	83.05M
Cash & Equivalents	9.52M	3.42M	11.74M	21.16M	5.13M	2.47M	10.65M	3.61M	18.92M	54.59M	13.17M	7.42M	134.55M	15.86M
Long Term Debt	-	-	5.31M	2.35M	0	0	14.33M	-	-	-	-	-	-	-
Total Liabilities	-	-	10.30M	8.57M	5.56M	14.95M	49.34M	15.11M	19.19M	57.13M	44.28M	13.69M	17.70M	33.41M
Current Liabilities	-	-	4.99M	5.85M	4.31M	11.09M	26.22M	12.16M	15.22M	19.89M	22.11M	4.62M	6.96M	12.94M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-10.16M	-14.57M	12.58M	-3.13M	-19.13M	-40.54M	-	-26.75M	-30.68M	-49.06M	-51.46M
Investing Cash Flow	-	-	-19.98K	-34.88K	-18.91M	865.46K	-443.00K	11.13M	-	-95.00K	-133.00K	356.00K	-81.72M
Financing Cash Flow	-	-	19.60M	-1.43M	3.74M	10.40M	12.56M	44.78M	-	-14.70M	25.04M	175.85M	14.59M
Capital Expenditure	-29.27K	-19.50K	-19.98K	-34.88K	-23.32K	-564.41K	-262.01K	-63.00K	-113.00K	-95.00K	-	-	-
Free Cash Flow	-	-	-10.18M	-14.61M	12.56M	-3.69M	-19.40M	-40.60M	-	-26.85M	-30.68M	-49.06M	-51.46M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-41.55M	-5.77M	127.15M	-118.59M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-1,394.6%	49.9%	-503.4%	-239.1%	-1,087.4%	-1,521.6%	-207.4%	-1,421.6%	-15,535.6%	-123,601.7%
Net Margin %	-	-	-	-1,428.6%	42.7%	-569.9%	-238.1%	-947.9%	-1,563.1%	-230.8%	-1,639.5%	-7,965.8%	-132,642.4%
ROE %	73.1%	61.0%	-80.2%	-7,957.2%	42.6%	-191.6%	-76.6%	-258.5%	-365.5%	381.7%	-431.9%	-26.4%	-94.2%
ROCE %	-	-233.7%	-69.6%	-1,103.6%	43.8%	-80.3%	-67.4%	-255.3%	-136.2%	-332.7%	-167.0%	-47.7%	-70.4%

Shareholding Pattern

Insiders

1.69%

Institutions

133.51%

Public Float

135.81%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	9.51%	5.10M	$84.51M
2	Blackrock Inc.	8.14%	4.37M	$72.34M
3	Deep Track Capital, Lp	6.73%	3.61M	$59.82M
4	Caligan Partners, LP	5.90%	3.16M	$52.43M
5	TCG Crossover Management, LLC	5.63%	3.02M	$49.99M
6	Affinity Asset Advisors, Llc	5.41%	2.90M	$48.05M
7	State Street Corporation	5.39%	2.89M	$47.88M
8	Farallon Capital Management LLC	4.66%	2.50M	$41.39M
9	Point72 Asset Management, L.P.	4.45%	2.39M	$39.55M
10	Avoro Capital Advisors LLC	4.35%	2.33M	$38.66M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AVTX

Google News ue, 23 Jun 2026

Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026 - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPaEZzYjBXbEdQaWRkbE16TG1FaTdlQ08yZFYwbW9wbWhvS09IWlI2a0lxWkVjejBWelZHLVc3ZDdzM2ZXaTFvY0dkcDQtWlpzdVNlSUljTExtZHluYVBPa0t1ODdLU3lYSmhYODIyVUw4dEh4dnNZVmVaa0VUVDZ6NHJ2dVRBR2REdGswVU…

Google News Sun, 06 Sep 2026

(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQMlBjbTVOMGZGVUd0bjJpSDUxVGkzRVRVSTI1ZWdkaDd6TTZLaFZyTzBjN2RzVm16dEJMd0djVzRRc0lyb2F2dlJ1U0Y3cm5Yalo5bWtEZjZ6U2ZVNkFxUTFZNzNjWlhreHpwZ1NRYnVmaDllUlh5Wi1wanBlcjJZVkItS3Q3ZkFWTnd6bV…

Google News Fri, 04 Sep 2026

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOU19hX2ZEWlpYUDBzN3kxSWJJWXg5T29iSmdzNDFTaXFNcXhaN2FrRGpENV81VGRhMWVPZTlEUllhNHd5N2tZNEVudFdVX1pwVXp1Skk1SGZZOU5QRXY3OXlnX0xDdXFiUThLbXc5ejE5dnBncVJDSWxmSVk0VmZURkdjZ0VrSm9XS2NyVX…

Google News Fri, 26 Jun 2026

AVTX Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBZcFZMeUVWd1NVNjZnNlN3R1BrNC1oYlBsMVhCYzgwaDV6YkFseWVRbGdmbFJ3eUR5T1FuX0lkYlFwN0lmZE1JTkoyaWZ6Rm0wU0dHOHRQZ29wVGJnNVYwR0RhMTZaMkh4ZGZzZzE4d01QYU92UjVoZHFn?oc=5" target="_blank">AVT…

Google News ue, 26 May 2026

AVTX - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBmUUxyRElUM2Y5Uk12V2lMOTR6VW13a0tQeElPVjlaSVdEMEJqZ2xLSWd2amVMVUdCdENJdG5uQUg0RWMxNUE?oc=5" target="_blank">AVTX</a>  <font color="#6f6f6f">Finviz</font>…

Google News ue, 02 Jun 2026

$AVTX stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQajd5TlpsTTNHWDJnQjI0MzdRNHBmVE5EWmFac1VCZHk0N0k4dUFhWXhrdTNTcFJwM0xVdFI5SkxfZkZNUVlJN3MwMDUzUHdtWmdLXzBhci0xMmpZR1Y2cVZscHlMM1dwSXY2dWhDVWJTajM2b2d0YS1QVWY5OWgzMW5VUllzQTlrdWlfdl…

AVTX — Frequently Asked Questions

What is the current share price of Avalo Therapeutics, Inc. (AVTX)?

As of 2026-09-19 21:16 PDT, Avalo Therapeutics, Inc. (AVTX) trades at $19.71 on NasdaqCM. Its 52-week range is $8.90 to $22.87.

What is the market capitalisation of AVTX?

Avalo Therapeutics, Inc. (AVTX) has a market capitalisation of $1.06B on NasdaqCM.

What is the P/E ratio of AVTX?

AVTX trades at a trailing price-to-earnings (P/E) ratio of -4.47. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.15.

What is the return on equity (ROE) of AVTX?

AVTX has a return on equity (ROE) of -36.27%. Its return on capital employed (ROCE) is -70.45%.

Is AVTX a good stock to buy?

This page provides a data-driven analysis of Avalo Therapeutics, Inc. (AVTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Avalo Therapeutics, Inc. AVTX R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Why Avalo Therapeutics, Inc. (AVTX) Is Among the Best Low Priced Stocks to Get Rich in 2026 - finance.yahoo.com

(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha

AVTX Forecast — Price Target — Prediction for 2027 - tradingview.com

AVTX - Finviz

$AVTX stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

AVTX — Frequently Asked Questions

What is the current share price of Avalo Therapeutics, Inc. (AVTX)?

What is the market capitalisation of AVTX?

What is the P/E ratio of AVTX?

What is the return on equity (ROE) of AVTX?

Is AVTX a good stock to buy?

Explore More